Stay tuned: Biogen’s numbers are great — it’s their worrisome future that leaves analysts skittish
Biogen came out with an upbeat assessment of their Q2 numbers today, discounting the arrival of a key rival for its blockbuster Spinraza franchise. But the top execs remain grimly determined to not say much anything new about the sore points that have dragged down its stock, including the future of its big investment in Alzheimer’s or how it plans to invest the considerable cash that the big biotech continues to reap.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.